Latest news
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - StocktwitsStocktwits · Fri, 07 Aug 2026 08:15:03 GMTGOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMillChartMill · Sat, 01 Aug 2026 02:28:51 GMTGossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update - Yahoo FinanceYahoo Finance · Sat, 01 Aug 2026 02:06:00 GMTWhy Gossamer Bio (GOSS) Is Up 42.9% After FDA Clears Path For Seralutinib NDA Submission - simplywall.stsimplywall.st · Thu, 30 Jul 2026 10:26:26 GMTBlackRock (GOSS) discloses 4.89M-share, 1% beneficial stake in Gossamer Bio - Stock TitanStock Titan · Wed, 29 Jul 2026 19:21:33 GMTUpdate: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment - MoomooMoomoo · Tue, 28 Jul 2026 09:13:31 GMTAfter missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration - Fierce BiotechFierce Biotech · Mon, 27 Jul 2026 07:00:00 GMTGossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business WireBusiness Wire · Mon, 27 Jul 2026 07:00:00 GMT